Literature DB >> 1648435

Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia.

J A Whitlock1, J P Greer, J N Lukens.   

Abstract

Thirty-seven children and adults who developed acute nonlymphocytic leukemia after the administration of chemotherapy that included etoposide or teniposide for a variety of hematologic and solid malignancies were identified. The secondary leukemia that occurred in these patients could be distinguished from the secondary leukemia that occurs after treatment with alkylating agents by the following: a shorter latency period; a predominance of monocytic or myelomonocytic features; and frequent cytogenetic abnormalities involving 11q23. Patients receiving an epipodophyllotoxin are at risk for developing secondary leukemia that has features distinct from the syndrome of secondary leukemia associated with alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648435     DOI: 10.1002/1097-0142(19910801)68:3<600::aid-cncr2820680326>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis.

Authors:  P H Hoeger; V R Nanduri; J I Harper; D A Atherton; J Pritchard
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

Review 2.  Avoiding chemotherapy related late effects in children with curable tumours.

Authors:  C R Pinkerton
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

3.  Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Authors:  M M Hawkins; L M Wilson; M A Stovall; H B Marsden; M H Potok; J E Kingston; J M Chessells
Journal:  BMJ       Date:  1992-04-11

Review 4.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 5.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

Authors:  Bart Barlogie; Guido Tricot; Jeff Haessler; Frits van Rhee; Michele Cottler-Fox; Elias Anaissie; James Waldron; Mauricio Pineda-Roman; Raymond Thertulien; Maurizio Zangari; Klaus Hollmig; Abid Mohiuddin; Yazan Alsayed; Antje Hoering; John Crowley; Jeffrey Sawyer
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

Review 7.  Cyclophosphamide and etoposide for non-small cell and small cell lung cancer.

Authors:  S M Grunberg
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 8.  Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management.

Authors:  Maurie Markman
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

9.  Molecular analysis of lambda bio transducing phage produced by oxolinic acid-induced illegitimate recombination in vivo.

Authors:  H Shimizu; H Yamaguchi; H Ikeda
Journal:  Genetics       Date:  1995-07       Impact factor: 4.562

Review 10.  Multilevel therapeutic targeting by topoisomerase inhibitors.

Authors:  P J Smith; S Souès
Journal:  Br J Cancer Suppl       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.